Technology ID
E-150-2013-0

Human Rotavirus Strains and Vaccines for Neonatal Childhood Protection

Linked ID
TAB-2695
Inventors
Baoming Jiang (CDC)
Jon Gentsch (CDC)
Roger Glass (CDC)
Yuhuan Wang (CDC)
Lead Inventors
Baoming Jiang (CDC)
Co-Inventors
Jon Gentsch (CDC)
Roger Glass (CDC)
Yuhuan Wang (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Novel rotavirus vaccines
  • Neonatal/childhood vaccination initiatives
  • Rotavirus surveillance programs, important for both developing and developed nations
This invention relates to rotavirus vaccine compositions and methods of vaccination. Rotaviral infection is the most commonly occurring gastrointestinal illness of children world, affecting both developed and developing economies. Additionally, rotavirus infections can affect livestock (especially calves and piglets), and resulting mortality/morbidity cause major economic losses for farmers and nations each year.

The vaccine strains include Rotavirus A CDC-9 (P[4]Gl) and CDC-66 (P[4]G2 serotype). These strains represent common rotavirus serotypes and may serve as improvements or alternatives to current live, oral rotavirus vaccine strains. Further, this technology has demonstrated efficacy in a large animal (piglets) modeling.
Competitive Advantages
  • Isolated strains are representative of those involved in community-acquired infection
  • Suitable for the development of improved, broadly effective rotavirus vaccines
  • Can be developed for injection and/or oral vaccine administration
  • Derived vaccines may be administered alone or in combination with other vaccines

Request More Info

Licensing Contact